NeuroVasx appoints distributor for Japan:
This article was originally published in Clinica
Executive Summary
Development-company NeuroVasx has appointed MDI Japan as distributor for its products there. The two companies hope to gain product registration in 1999. In November, NeuroVasx, of Plymouth, Minnesota, filed a 510(k) with the US FDA for its first product, the Sub-MicroInfusion catheter for the delivery of diagnostic agents to assess stroke. Separately, the US Patent and Trademark Office has allowed NeuroVasx a "substantial number of its claims" concerning its RPM macerator catheter. The product is used to combine the break-up of blood clots with the delivery of drugs for the treatment of acute stroke.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.